Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.34 |
| ▸ | KLK7 | P49862 | 2/20 | 0.34 |
| ▸ | RORC | P51449 | 4/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | STS | P08842 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3607486 | 1.00 | SPHK1 (0.41) | SPHK1KDM4EPKMBRD4ABCB1 | |
| SCHEMBL3607483 | 1.00 | SPHK1 (0.41) | SPHK1KDM4EPKMBRD4ABCB1 | |
| SCHEMBL3616041 | 0.90 | BRD4 (0.49) | SPHK1BRD4GPR119MEN1KMT2A | |
| SCHEMBL3616035 | 0.90 | BRD4 (0.49) | SPHK1BRD4GPR119MEN1KMT2A | |
| SCHEMBL3616039 | 0.90 | BRD4 (0.49) | SPHK1BRD4GPR119MEN1KMT2A | |
| SCHEMBL3604349 | 0.87 | BRD4 (0.41) | SPHK1KDM4EPKMBRD4ABCB1 | |
| SCHEMBL3604354 | 0.87 | BRD4 (0.41) | SPHK1KDM4EPKMBRD4ABCB1 | |
| SCHEMBL3604346 | 0.87 | BRD4 (0.41) | SPHK1KDM4EPKMBRD4ABCB1 | |
| SCHEMBL3618230 | 0.85 | BRD4 (0.40) | SPHK1KDM4EPKMBRD4ABCB1 | |
| SCHEMBL3618232 | 0.85 | BRD4 (0.40) | SPHK1KDM4EPKMBRD4ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2114906-B1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS FOR CNS DISORDERS | HOFFMANN LA ROCHE (CH) | 2014-08-06 | — | — | EP | disclosed |
| US-8604061-B2 | 2-aminooxazolines as TAAR1 ligands | HOFFMANN-LA ROCHE INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-20120196903-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | GALLEY GUIDO (DE) | 2012-08-02 | — | — | US | disclosed |
| US-20100120864-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | GALLEY GUIDO | 2010-05-13 | — | — | US | disclosed |
| US-20080261920-A1 | 2-Aminooxazolines as TAAR1 ligands | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120864-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | TAAR1, TAAR5, NPY2R | SPHK1 1971/4885KDM4E 2876/4885PKM 3125/4885 |
| US-20120196903-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | TAAR1, TAAR5, NPY2R | SPHK1 1969/4885KDM4E 2950/4885PKM 3040/4885 |
| US-20080261920-A1 | 2-Aminooxazolines as TAAR1 ligands | TAAR1, TAAR5, NPY2R | SPHK1 1971/4885KDM4E 2876/4885PKM 3125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.